Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects
NCT ID: NCT00634283
Last Updated: 2020-03-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
6 participants
INTERVENTIONAL
2008-02-29
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. long-term brain effects of a single course of antidepressant treatment
2. pharmaco-conditioning effects underlying antidepressant tolerance/sensitization
3. brain functional response to initial versus subsequent antidepressant trials in normal healthy subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiologic Monitoring of Antidepressant Response
NCT00792168
Physiologic Monitoring of Antidepressant Treatment Response
NCT00759317
Pharmacological Intervention in Depression After Traumatic Brain Injury
NCT00205491
Project to Improve Symptoms and Mood in People With Spinal Cord Injury
NCT00592384
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
NCT00839423
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
antidepressant-experienced
Subjects who had previously been exposed to active antidepressant medication (venlafaxine)
venlafaxine
venlafaxine IR 150mg
antidepressant-naive
Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)
venlafaxine
venlafaxine IR 150mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
venlafaxine
venlafaxine IR 150mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must be in overall good health (i.e., free of any medical condition known to affect brain function).
* Subject must have participated in former study, Physiologic Monitoring of Antidepressant Medication Effects in Normal Controls Subjects (IRB#: 00-11-038-13)
* Subject has had a normal physical exam within one year prior to entry of the study
* Capacity to give Informed Consent
Exclusion Criteria
* Subject meets DSM-IV Axis I criteria for a mood, anxiety, cognitive, or psychiatric disorder; or meets criteria for cluster A or B axis II diagnoses. These disorders will be determined on the basis of a structured assessment with the MINI (Mini International Neuropsychiatric Interview for DSM-IV Axis I Disorders)
* Subject has a history of current or past active suicidal ideation or suicide attempts.
* Subject has received treatment with an antidepressant medication or any medications that could influence brain function since his/her participation in the initial study
* Subject is using any of the following medications which interfere with EEG measures of brain function: Anticholinergics, Barbiturates, Benzodiazepines, Sedating Antihistamines (e.g. diphenhydramine (Benadryl) would be exclusionary, but not loratadine (Claritin))
* Subject has a history of seizures, brain surgery, skull fracture, significant head trauma, or previous abnormal EEG
* Subject is pregnant or planning on becoming pregnancy during course of the study
* Subject is a UCLA student or staff member directly under instruction or employment of any of the investigators
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrew F. Leuchter
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Leuchter, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Los Angeles (UCLA)
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hunter AM, Cook IA, Abrams M, Leuchter AF. Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes? Med Hypotheses. 2013 Dec;81(6):1004-11. doi: 10.1016/j.mehy.2013.09.016. Epub 2013 Sep 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-10-051
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.